The FDA has given its fast track designation to Amgen and Abgenix for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor, for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment. News that the cancer drug was being put on a swift review process sent shares of both companies higher this morning.
- read this press release for more